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INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive malignancy with few treatments producing prolonged remissions in high-risk patients. Hematopoietic cell transplant (HCT) may offer the best chance for a cure, but has been associated with high rates of treatment related mortality and relapse. Investigators have escalated chemotherapy and/or radiation doses to decrease relapse, but this strategy has been associated with substantial toxicity yielding no significant improvement in overall survival. 1 Monoclonal antibodies (mAb) targeting hematologic specific antigens have been used in radioimmunotherapy (RIT) studies as a means to deliver higher radiation doses prior to HCT. [2] [3] [4] [5] [6] One such target is CD45, a cell surface antigen highly expressed on hematologic tissues (~200,000 binding sites per cell) with minimal expression on non-hematologic tissues. 7, 8 CD45 is not extensively internalized after mAb binding, 9, 10 further making anti-CD45 RIT a viable approach for therapy of high-risk AML. In particular, anti-CD45 mAb coupled to 131 I has been shown to deliver an average 2-to-3-fold higher radiation-absorbed dose to spleen and bone marrow than to non-leukemic normal organs, and can be safely administered to high-risk patients with acute leukemia or myelodysplastic syndrome (MDS) in conjunction with standard high-dose chemotherapy and 12 Gray (Gy) total body irradiation (TBI). 5, 11 Favorable results suggesting improvements in survival have also been shown using this anti-CD45 RIT approach as part of a reduced-intensity HCT regimen in older relapsed/refractory AML patients with high disease burdens. 6 Despite these advances, limitations inherent to the radionuclides investigated thus far hinder more widespread use of RIT as an adjunct to HCT. The majority of RIT studies have used mAb labeled with beta-emitters such as 131 I and 90 Y. However, these radionuclides may generate non-specific cytotoxicity due to a cross-fire effect from their relatively longer path length (0.3-2.3 mm), and for 131 I, its associated gamma-emissions. Conversely, alpha-emitting radionuclides have the potential to deliver improved therapeutic ratios of absorbed radioactivity with less non-specific toxicity because of their very short path lengths (~60-80 µm), making For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From them attractive candidates for therapy of leukemias and elimination of minimal residual disease. [12] [13] [14] [15] [16] Differences in path lengths dictate that beta-emitters rely on cross-fire effect, irradiating bystander cells without the need to deliver the radionuclide directly to each malignant cell. The cross-fire effect from alpha-emitters is confined to smaller volumes, resulting in a cytotoxic effect in short range tracks near cells binding the radionuclide via the mAb. Moreover, alpha-emitting reagents have a high linear energy transfer (LET) because of the high decay energy (5-8 MeV) deposited over short distances that allows for potent and efficient cell kill, compared to beta-emitters such as 131 I and 90 Y with lower decay energies (0.66-2.3 MeV) and longer path lengths. 2 Only a few alpha-emitting radionuclides, however, are currently suitable for clinical application. 17 For the alpha-emitters with favorable radiobiologic characteristics, other issues such as availability, labeling chemistry, and in vivo stability, especially of astatinated macromolecules, have impacted their use in RIT. 14, 18, 19 Astatinated mAbs exhibit in vivo dehalogenation of mAb when labeled via conventional approaches, effectively hindering development of 211 At-based alpha targeted therapy. Using a novel approach to 211 At-label mAb, we have thus used the alpha-emitting radionuclide 211 At for anti-CD45 RIT of AML because it has a reasonable half-life (t 1/2 = 7.2 hours), a favorable energy profile (6.8 MeV, averages of two alpha decays, 5.9 and 7.5 MeV), and short path length (average range 55-70 µm). In this report we describe the efficacy and toxicity of 211 At-labeled-anti-CD45 RIT combined with HCT in a mouse model of syngeneic disseminated AML. These studies show that 211 At-anti-CD45 mAb can efficiently localize to sites of leukemia, and when used in lieu of TBI, this approach facilitates engraftment of donor bone marrow with minimal toxicity and significantly prolongs survival.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
METHODS
Mice: Female SJL/J mice, 6-to 12-weeks old, were purchased from Jackson Laboratories (Bar Harbor, ME), and housed at the Fred Hutchinson Cancer Research Center (FHCRC) in a pathogen-free environment under protocols approved by the Institutional Animal Care and Use Committee.
Cell Lines and Antibodies: Murine AML cells were produced by passage through SJL/J mice as previously described. 20, 21 Isotype-matched control antibody (polyclonal rat IgG) was purchased from Sigma Aldrich (St. Louis, MO). The rat IgG 2b anti-murine CD45 mAb (30F11) was purified as previously described. 20 Conjugation of 30F11 and Rat IgG with B10: Anti-CD45 mAb (30F11) or rat IgG antibody was diluted 1:1 with 100 mM HEPES buffer to yield 50 mM (with 150 mM NaCl, pH 8.6).
Isothiocyantophenethyl-ureido-closo-decaborate(2-) (B10-NCS) at 10 mg/mL in DMSO was added to antibody solution, 22 and the reaction proceeded overnight with gentle tumbling at room temperature. The next morning, the mixture was split into two equal fractions and passed over two PD-10 columns and collected in PBS. Protein fractions were combined, concentrated, and sterile filtered to yield 30F11-B10 or rat IgG-B10. 211 At-Labeling of 30F11-B10 and Rat IgG-B10: 211 At was isolated from an irradiated bismuth target by a wet chemistry approach as previously described. 22 The isolated 211 At solution was used directly in the labeling procedure. Briefly, a 250 µL solution of 500 mM sodium phosphate, pH 6.8 was combined with 250 µL 30F11-B10 or rat IgG-B10. To this solution, 500 µL of Na[ 211 At]At (3.5 mCi in water, pH 7) was added in the 30F11-B10 reaction, or 350 µL of Na[ 211 At]At (2.1 mCi in water, pH 7) in the rat IgG-B10 reaction, followed by 10 µL of an aqueous Chloramine-T solution (10 mg/mL). After 2 minutes at room temperature, the reaction For personal use only. on August 31, 2017. by guest www.bloodjournal.org From was quenched by adding 10 µL of sodium metabisulfite solution (10 mg/mL in water) to the 30F11-B10 or rat IgG-B10 reaction. Each mixture was then placed on a PD-10 column and eluted with PBS. The protein containing fractions were combined to give 211 At-B10-30F11 (75% radiochemical yield and 79% protein recovery) or 211 At-B10-rat IgG (72% radiochemical yield and 62% protein recovery). Purity of 211 At-labeled injectate was >99% by TLC.
Biodistribution Studies: Mice were injected with 1x10 5 SJL leukemia cells intravenously (i.v.).
Two days after injection of leukemia cells, 100 μg (0.67 nmol) of 30F11-B10 and rat IgG-B10 were trace-labeled with either 125 I as previously described, 20 Radiation Dosimetry: Radiation absorbed doses were calculated for blood and organs as previously described. 21 For mice that received 211 At-B10-mAb conjugates, we assumed a selforgan absorbed fraction of 1.0 and a cross-organ absorbed fraction of 0 due to the very short range of alpha particles. 23 RIT of Leukemic Mice: RIT studies were performed using 211 At-B10-mAb conjugates in groups of 10, and 5 days prior to study onset were placed on a diet containing Uniprim antibiotic (irradiated, 4100 ppm from Harlan Laboratories, Indianapolis, IN). Mice were injected i.v. with 1x10 5 SJL leukemia cells and two days later mice received 100 µg (0.67 nmol) of either 30F11-B10 or rat IgG-B10 labeled with 12, 20, or 24 µCi of 211 At. Two days after injection of 211 At-B10-For personal use only. on August 31, 2017. by guest www.bloodjournal.org From mAb, mice underwent syngeneic bone marrow transplant (BMT) receiving 15x10 6 donor bone marrow cells, without T-cell depletion, as described previously. 24 Mice were monitored daily for changes in appearance and body weight. Mice were euthanized if they became moribund from progressive leukemia or if they lost more than 30% of baseline weight. Survival curves were compared by the log-rank test (Mantel-Cox test), and reported only when statistically significant when less than the Bonferroni-corrected threshold for multiple comparisons.
Toxicity Assessments: Groups of 10 non-leukemia-bearing mice were treated with 12 or 24 µCi of 211 At-B10-mAb conjugate and rescued via BMT as described above. At 1, 2, 3, 4, 6, 8, and 25 weeks after BMT, blood was drawn via the retro-orbital plexus and complete blood counts were obtained. Serum was assayed for kidney function, by measuring blood urea nitrogen (BUN) and creatinine (Cr) levels, and liver function, by measuring enzymes alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate transaminase (AST). All toxicity tests were performed by Phoenix Central Laboratory (Everett, WA). 25 Values were compared with those obtained at the same time points from untreated age-matched control SJL/J mice.
RESULTS

Biodistribution of Radioactivity using 211 At-B10-Anti-CD45 mAb in SJL/J Leukemic Mice
To assess the ability of the mAb-B10 constructs to localize to leukemia targets, we performed biodistribution studies using radiolabeled anti-murine CD45 specific mAb (30F11)-B10 conjugates. As radioiodine has been reproducibly used in prior biodistribution studies, 20, 25 we labeled 30F11-B10 with 125 I and 211 At for comparison. Uptake of 125 I-B10-30F11 in the spleen was 67.6 ± 8% ID/g by 8 hours, and 24 hours after injection of 125 I-B10-30F11 the spleen retained more activity (42.3 ± 8% ID/g) than any other tissue at this same time point ( Figure 1A ).
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Since the novel alpha-labeling construct B10 did not appear to impede targeting given the excellent localization of 125 I-B10-30F11 to bone marrow and spleen, we then performed biodistribution studies using the alpha-emitter 211 At. One hour after 211 At-B10-30F11 injection, blood and spleen displayed the highest concentrations of radioactivity [32.3 ± 17% and 30.3 ± 14% ID/g, respectively ( Figure 1B) ]. In addition, blood clearance of 211 At-B10-30F11 was rapid, decreasing from 32.3 ± 17% ID/g 1 hour after injection to 11.7 ± 2% ID/g after 24 hours, while the spleen retained 79 ± 7.3% ID/g and the bone marrow (BM) retained 18 ± 3.8% ID/g after 24 hours. Importantly, 211 At-B10-30F11 did not exhibit excessive non-specific uptake in the kidneys, even without use of renal protective agents, with 10.2 ± 5.1%, 12.2 ± 2.6%, 10.9 ± 3.6%, and 8.4 ± 2.9% ID/g retained in kidneys 1, 3, 7 and 24 hours after injection of labeled 30F11-B10, respectively. Relatively low concentrations of radioactivity were delivered to nontarget organs such as liver, lung, small intestine, and colon after 24 hours (14.3 ± 1.3%, 8.4 ± 1.2%, 6.02 ± 0.7%, and 7.93 ± 1.3% ID/g, respectively). These biodistribution studies showed that both 125 I and 211 At localized to target tissues of bone marrow and spleen, with less nonspecific uptake in non-hematologic tissues.
At-B10-Anti-CD45 mAb Dosimetry
Using standard medical internal radiation dose methods 26 
Alpha-Camera Imaging
Alpha-camera imaging described previously was employed to further characterize the distribution of 211 At-B10-30F11 conjugate as some alpha-emitters have been known to exhibit heterogeneous distributions in targeted tissues at the sub-organ level. 27 Cryosections of spleen and femur from leukemia-bearing mice treated with 211 At-B10-30F11 were imaged with the alpha-camera technique at various time points after radiolabeled injections. At the 3-hour time point, alpha-camera imaging revealed that 211 At was distributed throughout the spleen and bone marrow, with some variability that correlates with sub-organ architecture. By imaging, the activity uptake in spleen ( Figure 2A ) was 33 ± 2% ID/g at 3 hours after injection of 80 µCi 211 At-B10-30F11, an uptake value in good agreement with the biodistribution data. Figure 2B presents a color-coded histogram of the activity distribution in a spleen section, where the activity uptake of the different subareas was normalized to the mean uptake for the whole spleen. More than 80% of the total section area was within a factor of 0.7 -1.3 of the mean activity. The highest concentrations were noted in areas corresponding to the marginal zone between red and white pulp. Alpha-camera imaging of cryo-sectioned femurs [ Figure 2C , yellow regions of interest (ROIs)] quantified the uptake in bone marrow to be 11 ± 2% ID/g at 3 hours after injection of 211 At-B10-30F11. These results correlated well with biodistribution studies ( Figure 1A) where 211 At-B10-30F11 demonstrated 11.2 ± 1.3% ID/g at the 3-hour timepoint. The activity distribution (normalized to the mean) along the bone marrow cavity of a femur was similar, where 85% of the area was within a factor of 0.7 -1.3 of the mean ( Figure   2D ). To further analyze activity distribution in the femur, 11 small ROIs were placed along the marrow cavity to quantify how their activity concentration varied as compared to the mean activity of the whole femur ( Figure 2C , magenta ROI). The variation in activity between the ROI were small, ranging from 0.9 to 1.25. The highest uptake was seen in the bone epiphyses.
At-Anti-CD45 RIT of Disseminated Murine Leukemia
Having demonstrated excellent localization of the anti-murine CD45 mAb-B10 conjugate in biodistribution and alpha-camera imaging studies, we assessed the therapeutic efficacy of 211 At-B10-30F11 in a clinically relevant disseminated murine myeloid leukemia model. SJL/J mice were injected with 1x10 5 SJL leukemic cells as previously described. 20 Figure 5E ). These data suggest that minimal toxicity is associated with anti-CD45 RIT employing 211 At and BMT in this model.
DISCUSSION
In this study we have demonstrated that anti-CD45 RIT using the alpha-emitting radionuclide 211 At in conjunction with BMT can prolong survival in mice with disseminated murine leukemia with minimal renal or hepatic toxicity. Biodistribution studies showed that the anti-CD45 30F11-B10 conjugate provides excellent localization of radioactivity to sites of leukemia (spleen and marrow), which was confirmed using alpha-camera imaging. Dosimetry estimates using 211 At-B10-30F11 revealed maximum absorbed doses delivered to splenic tissues harboring a high, leukemic cell burden, with ratios of absorbed dose per unit injected for target-to-non-target organs of 3.6, 4.4 and 6.2 for spleen-to-liver, spleen-to-lung, and spleen-tokidney, respectively. Importantly, dosimetric calculations demonstrated that a minimal radiation dose was delivered to the kidneys using this approach. When 24 µCi 211 At-B10-30F11-B10 was injected into mice, the kidneys were estimated to have an absorbed dose of 4.3 Gy, well within the tolerable safe dose of 10 Gy from previous studies on 211 At based RIT using renal filtration For personal use only. on August 31, 2017. by guest www.bloodjournal.org From capacity in mice. 28 These results may lessen concerns for radiation-induced nephritis, which has been linked to alpha-emitting radionuclides and their associated daughter radionuclides. 12, 14, 29 Minimal renal uptake also supports the viability, stability and targeted delivery of astatinated macromolecules via the conjugation chemistry of the B10-NCS (isothiocyanate-closo-decaborate) reagent, corroborating earlier studies that showed comparable in vivo stability of 211 At-and 125 I-labeled mAb at 24hr in canine biodistribution studies using 211 At-labeled via our B10 chemistry. 22 In RIT studies the delivery of 211 At-anti-CD45 RIT resulted in improved OS for leukemic mice that was most significant when combined with BMT, where 40% of mice treated at the highest dose (i.e., 24 µCi 211 At-B10-30F11) survived at least 180 days. Moreover, 211 At-anti-CD45 RIT was well tolerated with relatively minimal leukopenia that resolved by four weeks after BMT.
In addition to its tolerability, several other features suggest that alpha-emitting radionuclides may be better suited than the traditionally investigated beta-emitting radionuclides for certain clinical situations. Short effective path lengths and higher decay energies are some of the differentiating characteristics of alpha-emitting radionuclides compared to beta-or gamma-emitters. Alpha-emitting radionuclides decay with energies on the order of 4-8 MeV, which are deposited over their path length, usually on the order of 50-80 µm. Consequently, the LET of alpha particles approaches 100 KeV/µm, around which the radiobiological effectiveness has been shown to reach a maximum. On the other hand, radionuclides that decay via betaparticles, such as 90 Y with its mean energy of 2.4 MeV and significantly longer path length (2.7 mm) yields a lower LET of 0.22 KeV/µm. Other beta-emitting radionuclides studied in RIT, such as 131 I or 177 Lu, also have lower energies (0.66 and 0.5 MeV, respectively) and lower LET compared to alpha-emitters.
Dose calculations by other investigators have predicted differences in efficacy between alpha-and beta-emitters, largely from differences in their energy deposition. Energy from alpha emission is high and their short range such that only a few nearby cells are killed, whereas the energy deposition from beta-emitters is mostly deposited at For personal use only. on August 31, 2017. by guest www.bloodjournal.org From further distances, usually not killing the cell the radionuclide is attached to. 30, 31 Because betaemitters will deposit most of the energy away from the site of decay, 211 At could be more favorable than 90 Y for small tumor cell clusters, given more favorable tumor:normal tissue mean absorbed dose analysis when comparing 90 Y and 211 At distributed uniformly in spheres. 32 Thus, alpha-emitting radionuclides may be best suited for scenarios of circulating disease, such as leukemia, or in setting of minimum residual disease as their effective range of energy deposition is on the order of a few cell diameters. Conversely, these alpha-emitting radionuclides may be less effective in large, bulky tumors, requiring homogeneous distribution throughout the target volume.
RIT using alpha-emitting radionuclides have been investigated in a small number of human AML studies. Jurcic et al. 33 treated 18 AML patients using an anti-CD33 antibody (HuM195) labeled with 213 Bi, with 14 patients achieving a significant reduction in bone marrow leukemic blast cells. Subsequently the use of chemotherapy up-front to reduce the leukemic burden prior to administration of 213 Bi-HuM195 in an attempt to eliminate minimal residual disease showed encouraging improvements. 3, 34 Given the short half-life of 213 Bi (t 1/2 = 46 minutes), which can impact the logistics and limit widespread use of this approach, 225 Ac (t 1/2 = 10 days) has more recently been investigated as an alternative radionuclide for anti-CD33 (HuM195) RIT. 35 Prior alpha-emitter based RIT studies using 213 Bi to treat lymphomas in pre-clinical models have been associated with nephrotoxicity, likely from daughter radionuclides that have accumulated in the kidneys. Blocking agents such as the heavy metal chelating reagent DMPS have significantly lowered the 213 Bi absorbed dose to kidneys, where kidney doses have been decreased by as much as 60%, which may help render mAb labeled with alpha-emitting radionuclides useful for future clinical applications. 12, 21, 29 In fact, even 211 At-labeled mAb-B10 using a different B10 conjugation chemistry resulted in two cases of canine renal toxicity in a dose escalation study. 22 In the current study 211 At was linked to the anti-CD45 mAb via a lysine 
